UK Markets open in 6 mins

Silence Therapeutics plc (SLNCF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
3.25000.0000 (0.00%)
At close: 03:58PM EST

Silence Therapeutics plc

72 Hammersmith Road
London W14 8TH
United Kingdom
44 20 3457 6900

Full-time employees105

Key executives

NameTitlePayExercisedYear born
Mr. Craig A. Tooman M.B.A., MBAPres, CEO & Exec. Director452.77kN/A1966
Ms. Rhonda L. HellumsChief Financial Officer253.99kN/A1972
Dr. Giles V. Campion M.D.Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director581.07kN/A1954
Ms. Gem Gokmen HopkinsHead of IR & Corp. CommunicationsN/AN/AN/A
Mr. Eric FinkChief HR OfficerN/AN/A1978
Dr. John Strafford Ph.D.Sr. VP of Bus. Devel., Alliance Management & New Product Devel.N/AN/AN/A
Mr. Jørgen WittendorffSr. VP & Head of ManufacturingN/AN/AN/A
Dr. Barbara A. Ruskin J.D., Ph.D.Sr. VP and Chief Intellectual Property & Innovation OfficerN/AN/A1960
Dr. Eric Floyd Ph.D.Sr. VP of Regulatory Affairs & Quality AssuranceN/AN/A1962
Dr. Marie Wikstrom Lindholm Ph.D.Sr. VP & Head of Molecular DesignN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Corporate governance

Silence Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.